These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. Tsutamoto T, Kanamori T, Wada A, Kinoshita M. J Am Coll Cardiol; 1992 Sep; 20(3):541-6. PubMed ID: 1324959 [Abstract] [Full Text] [Related]
3. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Circulation; 1993 Jan; 87(1):70-5. PubMed ID: 8093432 [Abstract] [Full Text] [Related]
5. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Circulation; 1997 Jul 15; 96(2):509-16. PubMed ID: 9244219 [Abstract] [Full Text] [Related]
6. Relationship between plasma levels of atrial natriuretic peptide and cyclic guanosine monophosphate in patients with heart diseases. Nakaoka H, Imataka K, Kitahara Y, Fujii J, Ishibashi M, Yamaji T. Jpn Circ J; 1988 Jan 15; 52(1):30-4. PubMed ID: 2834571 [Abstract] [Full Text] [Related]
10. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Wada A, Tsutamato T, Maeda Y, Kanamori T, Matsuda Y, Kinoshita M. Am J Physiol; 1996 May 15; 270(5 Pt 2):H1819-24. PubMed ID: 8928891 [Abstract] [Full Text] [Related]
11. Heart is the Target Organ of Endogenous Cardiac Natriuretic Peptides. Tsutamoto T, Sakai H, Yamamoto T, Nakagawa Y. Int Heart J; 2020 Jan 31; 61(1):77-82. PubMed ID: 31956150 [Abstract] [Full Text] [Related]
12. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. J Am Coll Cardiol; 2000 Mar 01; 35(3):714-21. PubMed ID: 10716475 [Abstract] [Full Text] [Related]
16. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Nakamura M, Arakawa N, Yoshida H, Makita S, Niinuma H, Hiramori K. Am Heart J; 1998 Mar 01; 135(3):414-20. PubMed ID: 9506326 [Abstract] [Full Text] [Related]
19. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Osajima A, Okazaki M, Kato H, Anai H, Tsuda Y, Segawa K, Tanaka H, Tamura M, Takasugi M, Nakashima Y. Am J Nephrol; 2001 Apr 01; 21(2):112-9. PubMed ID: 11359018 [Abstract] [Full Text] [Related]
20. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. Tikkanen I, Helin K, Tikkanen T, Sybertz EJ, Vemulapalli S, Sariola H, Näveri H, Fyhrquist F. J Pharmacol Exp Ther; 1990 Aug 01; 254(2):641-5. PubMed ID: 2143536 [Abstract] [Full Text] [Related] Page: [Next] [New Search]